AQP4 and neuromyelitis optica: Long-term management often involves ongoing immunosuppressive agents such as eculizumab, inebilizumab-cdon, ravulizumab-cwvz, and satralizumab-mwge, which are FDA-approved for anti-AQP4-positive NMO [10].